Consistent with the clinical presentation of CMT2D, no myelination defects were observed in mice overexpressing mutant GARS1 (Seo et al., 2014a,b). This evidence concerns the gene GARS1 and Autosomal dominant Charcot-Marie-Tooth disease type 2D.